Premium
Characteristics of intestinal absorption and disposition of glycyrrhizin in mice
Author(s) -
Shibata Nobuhito,
Shimokawa Tatsuharu,
Jiang ZhiQiang,
Jeong YoungIl,
Ohno Tomoya,
Kimura Go,
Yoshikawa Yukako,
Koga Kenji,
Murakami Masahiro,
Takada Kanji
Publication year - 2000
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/1099-081x(200004)21:3<95::aid-bdd221>3.0.co;2-9
Subject(s) - bioavailability , glycyrrhizin , pharmacokinetics , pharmacology , chemistry , absorption (acoustics) , oral administration , plasma concentration , medicine , acoustics , physics
As basic studies to apply an intestinal pressure‐controlled colon delivery capsule (PCDC) for glycyrrhizin (GZ), the characteristics of intestinal absorption and disposition of GZ were investigated in mice. In the in vivo study, after intravenous (iv) administration of GZ, 10 mg/kg dose, plasma GZ disappeared from the systemic circulation with t 1/2(α) of 0.0063 h, thereafter, it slowly declined with t 1/2(β) of 15.23 h. The area under the plasma drug concentration versus time curve (AUC) values of iv (10 mg/kg), intracolonic (50 mg/kg) and intraduodenum (50 mg/kg) administrations were 115.1, 16.7 and 2.7 µgh/mL, respectively. The AUC values of plasma glycyrrhetic acid (GA), a degradation product after intracolonic and intraduodenum administrations were 2.8 and 8.4 µgh/mL, respectively. In the in situ closed loop study, the concentrations of GZ in plasma and liver after intracolonic administration were significantly increased (p<0.05) in comparison with those after intrajejunum or intraileum administration, while the concentration of GA in plasma and liver after intracolonic administration had trends to increase. These observations clearly suggest that the intracolonic administration is a useful way to improve the oral bioavailability of GZ and to enhance its pharmacological efficacy. These pharmacokinetic results of GZ suggest that GZ is a subject drug to be applied for the PCDC system we previously developed. The PCDCs formulation of GZ will enable us to carry GZ to the colon and enhance the oral bioavailability of GZ. Copyright © 2000 John Wiley & Sons, Ltd.